After years in the making, the much-awaited political agreement reached by the EU institutions on the so-called “EU pharma package” will...

The European Commission has published its long-awaited proposal for a regulation to simplify the EU Medical Devices Regulation (“EU...

In this third, and final, article of our three-part series - Thinking early: key legal points for early-stage biotech companies - we are...

In this second article of our three-part series - Thinking early: key legal points for early-stage biotech companies - we cover the...

In this first article of our three-part series - Thinking early: key legal points for early-stage biotech companies - we focus on the key...

On 16 October 2025, Adam Coughlin, Naoise Gaffney and Samuel Munday from Bristows attended TechBio UK, an annual conference hosted by the...

In August, luxury haircare company Olaplex Holdings, Inc. (Olaplex) acquired US biotechnology company Purvala Bioscience, Inc. (Purvala)1...

Although the UK’s new R&D tax relief regime came into force on 1 April 2024, many companies have only now completed their first...

At the start of the year, our editors (Xisca Borrás, Katie Cambrook and Aida Tohala) presented to you the 12th edition of our Biotech...

Earlier this month, Ellen Lambrix and Luca Cericola from Bristows’ Commercial & IP Transactions team attended the Licensing Executives...

We explore the complexities of navigating share option plans on both sides of the Atlantic. For companies looking to reward employees...

On 18 March 2025, Bristows attended the Wired Health 2025 conference, which took place at Kings Place in London. It was a day gathering...